Generation Bio (NASDAQ:GBIO) Second Quarter 2024 Results

Key Financial Results

• Revenue: US$4.09m (up 365% from 2Q 2023).

• Net loss: US$20.4m (loss narrowed by 34% from 2Q 2023).

• US$0.31 loss per share (improved from US$0.47 loss in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Generation Bio Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates significantly. Earnings per share (EPS) missed analyst estimates by 12%.

Looking ahead, revenue is expected to decline by 3.3% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 18%.

Performance of the American Biotechs industry.

The company's shares are down 24% from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for Generation Bio (1 can't be ignored!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.